RecruitingEssential Thrombocythemia

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

Eligible age

18+ yrs

Accepts

All genders

Locations

22 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.

Sponsor: Incyte Corporation

You may qualify if…

✓ Confirmed diagnosis of high-risk ET.
✓ Presence of mutCALR.
✓ Prior treatment with at least 1 cytoreductive therapy.

You may not qualify if…

✕ Presence of any hematologic malignancy other than ET.
✕ Major bleeding or thrombosis within the last 3 months prior to study enrollment.
✕ Any prior allogenic or autologous stem-cell transplantation.
✕ Unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic toxicities (Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy.
✕ Prior nonhematologic malignancy except for the following: Malignancy treated with curative intent and with no evidence of active disease for more than 2 years before screening. Adequately treated carcinoma in situ without current evidence of disease.
✕ Other protocol-defined Inclusion/Exclusion Criteria apply.